Physician profile
Michael Davis
NPI 1386639037
$685.66
in general payments reported to CMS, 2019-2025
10 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $14.57 · 2021: $102 · 2022: $72.09 · 2023: $49.07 · 2024: $221 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.21 | 2019-2025 | Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $148.53 | 2023-2025 | Entyvio |
| Lilly USA, LLC | $63.02 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $59.84 | 2022-2024 | Dificid, Bridion |
| Abbvie INC. | $54.48 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $50.93 | 2019 | |
| Bausch & Lomb Americas INC. | $24.76 | 2024 | Envista Mx60 Iol |
| Chiesi USA, INC. | $18.73 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $14.79 | 2022 | |
| Redhill Biopharma INC. | $13.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.